A recent survey conducted by Strupp et al. (2025), analyzed intervention trends across 234 respondents from 47 countries. This survey sought to investigate preferred treatment types for unilateral vestibular dysfunction (UVD), bilateral vestibular dysfunction (BVD), superior canal dehiscence syndrome (SCDS), benign paroxysmal positional vertigo (BPPV), and Meniere’s disease (MD). Across respondents, UVD was most commonly treated pharmacologically with oral steroids, antiemetics, and Betahistine. The second most common treatment choice for UVD was vestibular rehabilitation therapy. BVD was most often treated with vestibular rehabilitation therapy. SCDS was most typically treated surgically thorough a variety of approaches. BPPV was most commonly treated with canalith repositioning, and treatment types were typically canal specific. Finally, MD was often treated with a variety of medications including Betahistine, diuretics, oral steroids, antiemetics, and gentamycin; the second most common treatment for MD was surgical.
These authors noted fairly heterogeneous treatment trends across respondents, regardless of practice location. However, the authors also noted a lack of empirical evidence supporting the efficacy of many of the drugs that were reportedly used for the various vestibular conditions.
Reference
Strupp M, Kern L, Laurell G, Lehner L, Grill E, Strobl R. (2025) World-wide survey on the treatment of peripheral vestibular disorders. Front Neurol 16.
Recent Posts
Academy Supports Louisiana Legislation to Update Audiology Scope of Practice
The Louisiana legislature is currently considering House Bill 925 (HB 925), introduced during the 2026 regular session. This legislation aims to update statutory definitions related…
Update on Hearing Device Services Codes
As released publicly in the March 10, 2026, AMA’s Errata & Technical Corrections CPT® 2026, the parentheticals related to code 92628 (Evaluation for hearing candidacy)…
Intratympanic Steroid Therapy as a Salvage Treatment for Sudden Sensorineural Hearing Loss
Fernandez et al. (2026) completed a retrospective analysis of 86 patients seen between 2019 and 2024 with sudden sensorineural hearing loss (SSNHL). This analysis compared…


